Synapse - Works

Results (115605)

Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling

Meeting Abstract

Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant

Meeting Abstract

Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs): Updated results from a phase I/II study

Meeting Abstract

Budde, E. L.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M. J.; Gutierrez, N. C.; Marlton, P.; more...
Blood (2022)

Fulltext@MSK | Save

High-resolution single cell T-cell phenotyping of B-cell lineage lymphomas reveals unique immune signatures and potential targetable vulnerabilities

Meeting Abstract

El Daker, S.; Baik, J.; Dogan, A.; Zhu, M.; Roshal, M.; Galera, P. K.
Blood (2022)

Fulltext@MSK | Save

Mechanistic insights into immune related toxicities in subjects with relapsed/ refractory follicular lymphoma treated with zandelisib

Meeting Abstract

Sasi, B. K.; Martindale, S. P.; Shupe, S. J.; Fernandes, S. M.; Yadav, S.; Machado, J. H.; Phillips, T.; Zelenetz, A. D.; Brown, J. R.
Blood (2022)

Fulltext@MSK | Save

Efficacy and safety of single-agent zandelisib administered by intermittent dosing in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Final results of the tidal phase 2 study

Meeting Abstract

Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K. M.; Collins, G. P.; Bishton, M.; López Jiménez, J.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
Blood (2022)

Fulltext@MSK | Save

"Big Boom" (4 Gy x 1) radiation treatment (RT) versus "Big Boom" (2 Gy x 2) for non-Hodgkin lymphoma (NHL)

Meeting Abstract

Hajj, C.; Lebow, E. S.; Lee, J.; Fregonese, B.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K. R.; Freret, M. E.; Imber, B. S.; Yahalom, J.
Blood (2022)

Fulltext@MSK | Save

Population pharmacokinetics and exposure-response analyses from Phase I-III studies support copanlisib dose selection in relapsed indolent non-Hodgkin lymphoma

Meeting Abstract

Moss, J.; Garmann, D.; Austin, R.; Hiemeyer, F.; Matasar, M. J.; Zinzani, P. L.; Beckert, V.; Soler, L. M.; Childs, B. H.; Morcos, P. N.
Blood (2022)

Fulltext@MSK | Save

Updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of brexucabtagene autoleucel (KTE-X19) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

Meeting Abstract

Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
Blood (2022)

Fulltext@MSK | Save